Citrini Research is optimistic about AI pharmaceuticals, naming Charles River Laboratories and Revvity

Citrini Research, after testing Anthropic's Claude Science, stated that AI accelerated drug discovery has the potential to drive growth in the life sciences industry and is optimistic about benefiting stocks such as Charles River Laboratories and Revvity. Citrini Research believes that AI accelerated candidate drug design will increase the demand for experimental validation, bringing opportunities to companies that provide drug testing, experimental equipment, and research and development services. Charles River Laboratories is a drug testing service provider, while Revvity provides scientific research instruments and software. (Source: Bloomberg)